TRPV4
Transient receptor potential cation channel subfamily V member 4
As of the edition of 20 October 2026, TRPV4 (transient receptor potential cation channel subfamily V member 4, UniProt Q9HBA0) has 2 drugs tested at it and 2 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9HBA0
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 19
- Disease areas
- Heart and blood vessels; Lungs and airways; Eye
- Registered trials of its drugs
- 5
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| GSK2798745 | Stopped | Phase 2 | none listed |
| Butamben | Marketed | No phase stated | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| GSK | Route A |
The other 1 company at TRPV4
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at TRPV4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.